Business
4basebio Plc - 4basebio Signs Clinical Supply Agreement to Support Phase II Clinical Trial
4basebio Plc - 4basebio Signs Clinical Supply Agreement to Support Phase II Clinical
About this update from 4basebio Plc
[{"type":"text","content":" 4basebio PLC (\"4basebio\" or the \"Company\") 4basebio Signs Clinical Supply Agreement to Support Phase II Clinical Trial · Oncology focused biotech to utilise 4basebio's opDNA® technology to support Phase II clinical trial of immunotherapy candidate · Multi-year, seven-figure revenue stream reflecting increased commercial momentum CAMBRIDGE, UK - 20 May 2026 - 4basebio PLC (AIM: 4BB), a company pioneering an enzymatically-produced DNA technology serving the next generation genetic medicines markets, announces that it has signed a Clinical Supply Agreement with a leading cancer immunotherapy innovator (\"the Client\") to provide GMP-grade opDNA® starting material for its latest clinical programme. Under the terms of the agreement, 4basebio will supply synthetic DNA to be used as a critical material for the Client's immunotherapy candidate for an upcoming Phase II clinical trial. The agreement is expected to provide an approximate seven-figure revenue stream over the next 12 months, reflecting 4basebio's unique capability to provide a safer, cost-effective replacement for plasmid DNA in the development of genetic medicines. By leveraging 4basebio's enzymatic, cell-free manufacturing process, the Client will enhance the safety of its therapeutic product by fully eliminating microbial contamination and the inclusion of antibiotic resistance genes, helping to accelerate its development timelines from sequence to clinic. Dr. Amy Walker, Chief Executive Officer at 4basebio, added: \"This partnership demonstrates how our proprietary DNA technology platform can help clients overcome complex manufacturing hurdles and bring safer and effective therapies to patients. We continue to see growing interest in our DNA molecules across the genetic medicine space and are delighted to support our partners through their clinical trials.\" This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 as amended by regulation 11 of the market abuse (amendment) (EU Exit) regulations 2019/310. For further enquiries, please contact: 4basebio PLC Dr Amy Walker, CEO +44 (0)12 2396 7943 Cairn Financial Advisers LLP (Nominated Adviser) Jo Turner / Sandy Jamieson / Ed Downes +44 (0)20 7213 0880 Cavendish Capital Markets Limited (Joint Broker) Geoff Nash / Nigel Birks +44 (0)20 7220 0500 RBC Capital Ma...